Innovent Biologics' (HKG:1801) attributable loss narrowed 91% to 94.6 million yuan in 2024 from 1.03 billion yuan in 2023, according to a Wednesday filing with the Hong Kong bourse.
The drugmaker's loss per share dropped to 0.06 yuan from 0.66 yuan a year earlier. Analysts at Visible Alpha estimated a loss per share of 0.38 yuan.
Revenue grew 52% to 9.42 billion yuan from 6.21 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 8.36 billion yuan.
Shares surged 14% in Thursday's midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.